The selective VEGFR inhibitor PTK787/ZK 222584 represses the activities of VEGFR-negative bone marrow-derived mesenchymal stem cells

Cancer Biology and Therapy

Volumn 8, Issue 13, 2009, Pages 1249-1251

  Sano, Motoaki ^a   Fukuda, Keiichi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti tumor therapy; Mesenchymal stem cells; PDGF; PZK ZK (Vatalanib); VEGF; VEGFR inhibitor

Indexed keywords

ADENOSINE TRIPHOSPHATE; BEVACIZUMAB; IMATINIB; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN A; VATALANIB;

AUTOPHOSPHORYLATION; BLEEDING; BONE MARROW CELL; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONGESTIVE HEART FAILURE; CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; ENZYME PHOSPHORYLATION; HEMATOPOIETIC STEM CELL; HUMAN; HYPERTENSION; INTESTINE PERFORATION; MESENCHYMAL STEM CELL; NONHUMAN; NOTE; PROTEIN BINDING; PROTEIN INTERACTION; PROTEINURIA; SIGNAL TRANSDUCTION; SOLID TUMOR; STROMA CELL; THROMBOEMBOLISM; TUMOR CLASSIFICATION; TUMOR GROWTH;

EID: 68149158206     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.13.8996     Document Type: Note

References (27)

1. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999; 103:697-705.
2. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143-7.
3. Picinich SC, Mishra PJ, Glod J, Banerjee D. The therapeutic potential of mesenchymal stem cells. Cell- & tissue-based therapy. Expert Opin Biol Ther 2007; 7:965-73.
4. Ayach BB, Yoshimitsu M, Dawood F, Sun M, Arab S, Chen M, et al. Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after myocardial infarction. Proc Natl Acad Sci USA 2006; 103:2304-9.
5. Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H, et al. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 2004; 104:3581-7.
6. Tomita Y, Matsumura K, Wakamatsu Y, Matsuzaki Y, Shibuya I, Kawaguchi H, et al. Cardiac neural crest cells contribute to the dormant multipotent stem cell in the mammalian heart. J Cell Biol 2005; 170:1135-46.
7. Psaltis PJ, Zannettino AC, Worthley SG, Gronthos S. Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells 2008; 26:2201-10.
8. Endo J, Sano M, Fujita J, Hayashida K, Yuasa S, Aoyama N, et al. Bone marrow derived cells are involved in the pathogenesis of cardiac hypertrophy in response to pressure overload. Circulation 2007; 116:1176-84.
9. Wels J, Kaplan RN, Rafii S, Lyden D. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev 2008; 22:559-74.
10. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315:1650-9.
11. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE 2009; 4:4992.
12. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60:2178-89.
13. Hess-Stumpp H, Haberey M, Thierauch KH. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Chembiochem 2005; 6:550-7.
14. Roorda B, ter Elst A, Diks SH, Meeuwsen-de Boer TGJ, Kamps WA, de Bont ESJM. PTK787/ZK 222584 inhibits tumor growth promoting mesenchymal stem cells: Kinase activity profiling as powerful tool in functional studies. Cancer Bio Ther 2009; 8.
15. Ball SG, Shuttleworth CA, Kielty CM. Platelet-derived growth factor receptor-alpha is a key determinant of smooth muscle alpha-actin filaments in bone marrow-derived mesenchymal stem cells. Int J Biochem Cell Biol 2007; 39:379-91.
16. Ball SG, Shuttleworth CA, Kielty CM. Mesenchymal stem cells and neovascularization: role of platelet-derived growth factor receptors. J Cell Mol Med 2007; 11:1012-30.
17. Ball SG, Shuttleworth CA, Kielty CM. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol 2007; 177:489-500.
18. Assoian RK. Anchorage-dependent cell cycle progression. J Cell Biol 1997; 136:1-4.
19. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22:1276-312.
20. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79:1283-316.
21. Jechlinger M, Grunert S, Tamir IH, Janda E, Lüdemann S, Waerner T, et al. Expression profiling of epithelial plasticity in tumor progression. Oncogene 2003; 22:7155-69.
22. Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 2003; 3:439-43.
23. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7:987-9.
24. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-5.
25. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007; 130:691-703.
26. Chen MH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008; 118:84-95.
27. Mishra PJ, Glod JW, Banerjee D. Mesenchymal stem cells: flip side of the coin. Cancer Res 2009; 69:1255-8.